9939 Stock Overview
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Kintor Pharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.94 |
| 52 Week High | HK$5.83 |
| 52 Week Low | HK$0.81 |
| Beta | -0.19 |
| 1 Month Change | 5.62% |
| 3 Month Change | -25.40% |
| 1 Year Change | -83.00% |
| 3 Year Change | -98.68% |
| 5 Year Change | n/a |
| Change since IPO | -95.63% |
Recent News & Updates
Recent updates
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Nov 16
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Apr 28Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Dec 06Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?
Sep 01Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings
Feb 17What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)?
Dec 23
Shareholder Returns
| 9939 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 10.6% | 5.7% | 3.6% |
| 1Y | -83.0% | -40.7% | -10.1% |
Return vs Industry: 9939 underperformed the Hong Kong Biotechs industry which returned -40.7% over the past year.
Return vs Market: 9939 underperformed the Hong Kong Market which returned -10.1% over the past year.
Price Volatility
| 9939 volatility | |
|---|---|
| 9939 Average Weekly Movement | 19.7% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 9939's share price has been volatile over the past 3 months.
Volatility Over Time: 9939's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 225 | Youzhi Tong | www.kintor.com.cn |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People’s Republic of China and internationally. The company’s products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline comprises ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours.
Kintor Pharmaceutical Limited Fundamentals Summary
| 9939 fundamental statistics | |
|---|---|
| Market cap | HK$420.65m |
| Earnings (TTM) | -HK$1.15b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 9939 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9939 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥42.23m |
| Gross Profit | -CN¥42.23m |
| Other Expenses | CN¥1.02b |
| Earnings | -CN¥1.06b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 53.9% |
How did 9939 perform over the long term?
See historical performance and comparison